Lead Sponsor

U3 Pharma GmbH

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Pathologically or cytologically documented advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available, or the patient refuses standard therapy.
•Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
•Men or women at least 18 years of age
•Adequate hematologic, cardiac, renal, hepatic, metabolic, and coagulation function

•Presence of untreated or symptomatic brain metastasis.
•Presence of ascites or pleural effusion requiring chronic medical intervention.
•Uncontrolled hypertension
•Concurrent or previous (within 1 week of study day 1) anticoagulation therapy, except low-dose warfarin (≤ 2 mg/day) or low dose,low molecular weight heparin for prophylaxis against central venous catheter thrombosis.
•Recent major surgical procedure or not yet recovered from major surgery
•Recent participation in clinical drug trials.
•Participation in other investigational procedures.
•Unresolved toxicities from prior anti-cancer therapy
•Patient who is pregnant (e.g. positive human choriogonadotropin \[HCG\] test) or nursing.